Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
Author: Karlan, B.
Oza, A.
Richardson, G.
Provencher, D.
Hansen, V.
Buck, M.
Chambers, S.
Ghatage, P.
Pippitt Jr, C.
Brown III, J.
Covens, A.
Nagarkar, R.
Davy, M.
Leath III, C.
Nguyen, H.
Stepan, D.
Weinreich, D.
Tassoudji, M.
Sun, Y.
Vergote, I.
Citation: Journal of Clinical Oncology, 2012; 30(4):362-371
Publisher: Amer Soc Clinical Oncology
Issue Date: 2012
ISSN: 0732-183X
Statement of
Beth Y. Karlan, Amit M. Oza, Gary E. Richardson, Diane M. Provencher, Vincent L. Hansen, Martin Buck, Setsuko K. Chambers, Prafull Ghatage, Charles H. Pippitt Jr, John V. Brown III, Allan Covens, Raj V. Nagarkar, Margaret Davy, Charles A. Leath III, Hoa Nguyen, Daniel E. Stepan, David M. Weinreich, Marjan Tassoudji, Yu-Nien Sun and Ignace B. Vergote
Abstract: <h4>Purpose</h4>To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer.<h4>Patients and methods</h4>Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive paclitaxel (80 mg/m(2) once weekly [QW], 3 weeks on/1 week off) plus intravenous AMG 386 10 mg/kg QW (arm A), AMG 386 3 mg/kg QW (arm B), or placebo QW (arm C). The primary end point was progression-free survival (PFS). Secondary end points included overall survival, objective response, CA-125 response, safety, and pharmacokinetics.<h4>Results</h4>One hundred sixty-one patients were randomly assigned. Median PFS was 7.2 months (95% CI, 5.3 to 8.1 months) in arm A, 5.7 months (95% CI, 4.6 to 8.0 months) in arm B, and 4.6 months (95% CI, 1.9 to 6.7 months) in arm C. The hazard ratio for arms A and B combined versus arm C was 0.76 (95% CI, 0.52 to 1.12; P = .165). Further analyses suggested an exploratory dose-response effect for PFS across arms (Tarone's test, P = .037). Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively. The incidence of grade ≥ 3 adverse events (AEs) in arms A, B, and C was 65%, 55%, and 64%, respectively. Frequent AEs included hypertension (8%, 6%, and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C, respectively), and hypokalemia (21%, 15%, and 5% in arms A, B, and C, respectively). AMG 386 exhibited linear pharmacokinetic properties at the tested doses.<h4>Conclusion</h4>AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile. The data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.
Keywords: Humans
Peritoneal Neoplasms
Ovarian Neoplasms
Fallopian Tube Neoplasms
Neoplasm Recurrence, Local
Recombinant Fusion Proteins
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Survival Analysis
Double-Blind Method
Aged, 80 and over
Middle Aged
Rights: © 2011 by American Society of Clinical Oncology
DOI: 10.1200/JCO.2010.34.3178
Published version:
Appears in Collections:Aurora harvest 4
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.